Drugs and Disease

Symposium organized by
The Royal College of Pathologists
delivered in London in February 1975

Edited by
SHEILA WORLLEDGE

Published for The Royal College of Pathologists by the
Journal of Clinical Pathology, BMA House, Tavistock Square
London WC1H 9JR England
£3-00
Index

Absorption, drug interactions during, 95

ADJEPON-YAMOAH, K. K. See PRESCOTT, L. F., FORREST, J. A. H., ADJEPON-YAMOAH, K. K., and FINLAYSON, N. D. C.

Adrenergic neuron-blocking drugs in hypertension, 36

—— receptor-blocking drugs, 37

Aerosols, bronchodilator, prescribing of, survey of, 11

Agranulocytosis, drug-induced, 46, 47

Amidopyrine, agranulocytosis induced by, 46, 48

Anaemia, haemolytic, drug-induced, 46, 47

Anesthesia, mechanism of, 1

Analgic, nephropathy, 14

——, aetiology of, 18

—— and neoplasia, 20

——, clinical syndrome of, 14

——, pathogenesis of, 17

——, pathological diagnosis of, 17

——, pathology of, 14

Ancrod, 52

Anion-exchange resins in hyperlipoproteinemia, 109, 110

Antibiotics, sale of, survey of, 12

Antibodies, drug-specific, damage to drug-coated cells by, 47

Anticoagulants, 51

——, indications for, 52

Antidiabetic drugs in relation to vascular events, evaluation of, 99

——, oral, prescribing of, survey of, 11

Antiplatelet agents, 50

Arsenic Act (1851), 119

Aspirin and renal disease, 19

Autoimmune phenomena induced by drugs, 47

Autonomic ganglion-blocking drugs in hypertension, 36

Azathioprine, toxicity of, 26, 30, 31, 32

Bacterial infections and immunosuppressive agents, 28

BARNES, J. M.: The widespread use of pesticides, 115

Bedford 8½-year Analysis of tolbutamide in diabetes, 101

—— Tolbutamide Trial in diabetes, 100

Blood cells, damage mediated by immune complexes, 46

—— disorders, drug-induced, 46

—— dyscrasias, allergic, drug-induced, immunological mechanisms in, 46

——, serological methods for detection of, 48

British Pharmacopoeia, 119

Bronchodilator aerosols, prescribing of, survey of, 11

CAMERON, J. S.: Problems with immunosuppressive agents in renal disease, 24

Cardiovascular disorders, effect of antidiabetic agents, evaluation of, 99

Central nervous system and antihypertensive drugs, 38

Cefalothin, anaemia and thrombocytopenia induced by, 47

Cholestasis associated with drugs, 73

Cholestatic hepatitis associated with drugs, 67

CLARKE, A. E.: The effect of oxygen on the lung, 75

Clofibrate in hyperlipoproteinemia, 108, 110

Clonidine in hypertension, 37

Clothing and fibrolysis, 50

Committee on Safety of Medicines, 121

Contraceptive pill, skin reactions to, 55

Coronary heart disease and hypolipaemic drugs, 106

Coumarin compounds, 51

Cyclic nucleotides, effect on red cell shape, 41

Cyclophosphamide, toxicity of, 27, 30, 31

Dangerous Drugs Acts, 120

DDT, 116

Diabetes, phenformin in, trials of, 102, 103

——, tolbutamide in, mortality and morbidity, 101

——, trials of, 100, 101

Diclophane, 116

Diets, lowering of serum lipids by, effect on coronary heart disease, 112

——, restriction in hyperlipoproteinemia, 111

Dinitroorthocresol, 115

Diuretics, thiazide, in hypertension, 37

Drugs, action, mechanisms of, 1

——, specific and nonspecific, 1

——, acute liver injury associated with, 66

——, adverse reactions to and interactions of, incidence of, 94

——, incidence of, 7

——, intensive monitoring of, 9

——, literature on, 8

——, registry reports of, 8

—— and kidney, 14

—— and liver, 62

—— and lung, 75

—— and skin, 54

——, as cause of death, 12

——, autoimmune phenomena induced by, 47

—— benefits and hazards, 94

——, blood disorders induced by, 40

——, dyscrasias induced by, immunological mechanisms in, 46

——, serological methods for detection of, 48

——, cells coated with, damage by drug-specific antibodies to, 47

——, chronic liver disease associated with, 71

——, clinical aspects of, and skin diseases, 54

——, effect on red cell membranes, and factors determining normal red cell shape, 40

——, fixed drug eruptions, 60

—— in hypertension, 36

——, interactions and lethal combinations, 94

——, at sites of metabolism and excretion, 96

——, before administration, 94

——, during absorption, 95

——, in gut, 94

——, pharmacodynamic, 96

——, plasma-protein-binding, 95

——, metabolism in liver disease, 62

——, safety of, legislation on, 119

——, skin reactions to, immunological mechanisms in, 58

——, therapeutic audit of, 10

——, toxicity, molecular basis of, 1

——, with direct action on vascular resistance, 37

Epidermal necrosis, toxic, due to drugs, 56

Erythema due to drugs, 56

Exanthematous eruptions due to drugs, 54

Fat solubility and anaesthetics, 1

Fibrinolysis and clotting, 50

——, pharmacological enhancement of, 52

Fibrinolytic therapy, indications for, 53

FINLAYSON, N. D. C. See PRESCOTT, L. F., FORREST, J. A. H., ADJEPON-YAMOAH, K. K., and FINLAYSON, N. D. C.

FORREST, J. A. H. See PRESCOTT, L. F., FORREST, J. A. H., ADJEPON-YAMOAH, K. K., and FINLAYSON, N. D. C.

Fungal infections and immunosuppressive agents, 28

Ganglion-blocking drugs, autonomic, in hypertension, 36

Gin Acts, 119

Granuloma, Wegener's, immunosuppressive agents in, 25

Haemolytic anaemia, drug-induced, 46, 47

Halothane anaesthesia, severe hepatic necrosis after, 68

Hamman-Rich syndrome, 79

Heparin, 51

Hepatic necrosis, severe, associated with drugs, 68

Hepatitis, acute, associated with drugs, 67

——, cholestatic, associated with drugs, 67

Hepatocellular disease associated with drugs, 72

HOWARD, A. N.: Hypolipaemic drugs and coronary heart disease, 106

Hydralazine, autoimmune phenomena induced by, 47

—— in hypertension, 37

Hyperlipoproteinemia, 106

——, advisability of treatment in, 113

——, dietary restriction in, 111

——, drugs used in, 108

——, in combination for, 110

Hypersensitivity reactions mediated by T lymphocytes, 59
Hypertension, drug treatment of, 36
— treatment regimes in, 38
Hypnotic drugs, prescribing of, survey of, 10
Hypoglycaemic drugs, oral, prescribing of, survey of, 11
Hypolipaemic drugs and coronary heart disease, 106
— types and effects, 108
— used in combination, 110
Immune complexes, cell damage mediated by, 46
Immunological mechanisms in drug-induced blood dyscrasias, 46
— in skin reactions to drugs, 58
Immunosuppressive agents in renal disease, 24
— unexpected effects of, 25
Infection, facilitation of, and immunosuppressive agents, 27
Intestine, drug interactions in, 94
JACOB, H. S.: Effect of drugs on red cell membranes: insights into normal red cell shape, 40
KEEN, H.: Antidiabetic agents and vascular events, 99
KENNEDY, A.: Analgesic nephropathy, 14
Kidney and drugs, 14
Legislation and drug safety, 119
Leucocyte methods for detection of drug-induced allergic blood dyscrasias, 48
Leucopenia, drug-induced, 46, 47
Lichen planus, drug reactions resembling, 55
Light sensitivity due to drugs, 55
Lipids, serum, lowering by diet in coronary disease, 112
— by drugs in coronary disease, 111
— role in coronary heart disease, 106
Lipoid nephrosis, immunosuppressive agents in, 25
Lipophailes, action, modulation of specificity in, 5
— toxicity, possible patterns of, 4
Liver and drugs, 62
— disease, chronic, associated with drugs, 71
— drug metabolism in, 62
— in acute disease, 63
— in chronic disease, 64
— injury, acute, associated with drugs, 66
—, attribution to particular drug, 68
— chronic effects of single episodes, 71
— criteria for drug toxicity as cause, 69
— pigmentation associated with drugs, 73
— tumours and tumour-like nodules associated with drugs, 73
— vascular lesions of, associated with drugs, 73
Lung and drugs, 75
— effect of oxygen, 75
— lesions due to oxygen in adults, 75
— — in children, 76
— — in experimental animals, 76
— — influence of temperature and pressure, 78
— — mechanism of, 78
— — types of, 78
— pathology in parquat poisoning, 81
— vasculature, histopathology in parquat poisoning, 91
Lupus erythematosus, systemic, drugs as precipitating factor in, 56
— glomerulonephritis, immunosuppressive agents in, 24
Lymphocytes, T cell-mediated hypersensitivity reactions, 59
Marrow depression and immunosuppressive agents, 27
Medicines Act (1968), 119, 121
Methotrexate, hepatotoxic effects of, 72
Methyldopa, autoimmune phenomena induced by, 47, 48
MIESCHER, P. A.: See NYDEGGER, U., and MIESCHER, P. A.
Misuse of Drugs Act, 120
Molecular basis of drug toxicity, 1
Neomycin in hyperlipoproteinaemia, 109
Neoplasia and analgesic nephropathy, 20
Nephroathy, analgesic. See Analgesic nephropathy
Nephrotic syndrome, minimal-change, immunosuppressive agents in, 225
Neurone-blocking drugs, adrenergic, 36
Nicotinic acid in hyperlipoproteinaemia, 109
Nucleotides, cyclic, effect on red cell shape, 41
NYDEGGER, U., and MIESCHER, P. A.: Immunological mechanisms in drug-induced blood dyscrasias, 46
Oestrogens in hyperlipoproteinaemia, 110
Oncogenesis and immunosuppressive agents, 31
Oxygen at atmospheric pressure, 75
— effect on lung, 75
— hyperbaric, 75
— therapy, influence on parquat poisoning, 90
— See also Lung lesions due to oxygen
Oxyphenisatin jaundice, 72
Paracetamol, acute liver injury due to, 66
Parquat, hazards of, 116
— poisoning, destructive phase of, 81
—, influence of oxygen therapy, 90
— lung, pathology in, 81
— mechanism of toxicity in, 90
— proliferative phase in animals after repeated doses, 85
—, after single dose, 83
—, in man, 89
— pulmonary vasculature in, histopathology of, 91
TREATMENT OF, 92
PATON, W. D. M.: The molecular basis of drug toxicity, 1
Penicillin, immune haemolytic anaemia induced by, 47
Pesticides, poisoning by, incidence of, 117
Phenacetin and drugs, 55
Pharmacology Act (1968), 119
— and Poisons Act, first, 120
Phenacetin and renal disease, 19
Phenformin in diabetes, trials of, 102, 103
Pigmentation of liver associated with drugs, 73
Plasma-protein-binding drug interactions, 95
Platelet methods for detection of drug-induced allergic blood dyscrasias, 48
Prazosin in hypertension, 38
PRENTICE, C. R. M.: Clotting and fibrinolysis, 50
Procainamide, autoimmune phenomena induced by, 47
Propranolol and renal secretion in hypertension, 38
Psoriasis, drug reactions resembling, 55
Receptor-blocking drugs, adrenergic, 37
Red cell membranes, effect of drugs, and factors determining normal red cell shape, 40
— methods for detection of drug-induced allergic blood dyscrasias, 48
—, shape, effect of cyclic nucleotides, 41
—, role of spectrin, 43
Renal disease, immunosuppressive agents in, 24
— transplantation, immunosuppressive agents in, 24
Renin secretion, inhibition of, and antihypertensive drugs, 38
Resins, anion-exchange, in hyperlipoproteinaemia, 109, 110
Respirator lung syndrome, 75
RICHENS, A.: Drug interactions and lethal drug combinations, 94
Safety of Drugs Committee, 120
SCHUEB, P. J.: Long-term effects on the liver, 71
SCONEN, C. E.: Legislation and drug safety, 119
Sedormid, thrombocytopenia induced by, 46, 48
Serum lipids, lowering by diet in coronary disease, 112
—, by drugs in coronary disease, 111
—, role in coronary heart disease, 106
Skin and drugs, 54
— diseases and clinical aspects of drugs, 54
—, fixed drug eruptions in, 60
— reactions to drugs, immunological mechanisms in, 58
— sensitizers inducing reactions to systemic drugs, 54
SMITH, P., and HEATH, D.: The pathology of the lung in parquat poisoning, 81
SNEDDON, I. B.: The clinical aspects of drugs and disease of the skin, 54
Sodium nitroprusside in hypertension, 38
Spectrin, role in red cell shape, 43
Spherocytosis, hereditary, 40, 41, 44
TALBOT, i. c.: Acute liver injury, 66
Teratogenicity and immunosuppressive agents, 31
Thalidomide, 8
Therapeutic Substances Act, 120
Thiazide diuretics in hypertension, 37
Thrombocytopenia, drug-induced, 46, 47, 48

Index
Index

Thrombolytic therapy, 52
D-Thyroxine in hyperlipoproteinaemia, 109
Tolbutamide in diabetes, mortality and morbidity analysis, 101
— — —, trials of, 100, 101
Transplantation, renal, immunosuppressive agents in, 24
Tumours and tumour-like nodules of liver associated with drugs, 73
TURK, J. L.: Immunological mechanisms in the reaction between drugs and the skin, 58
University Group Diabetes Programme, 101, 102
Urticarial reactions to drugs, 55

Vascular lesions of liver associated with drugs, 73
— — resistance, drugs acting directly on, 37
Veterinary Products Committee, 121
Viral infections and immunosuppressive agents, 28
WADE, O. L.: The incidence of adverse reactions to drugs, 7
Wegener's granuloma, immunosuppressive agents in, 25
Whitehall Phenformin Trial in diabetes, 103
YAMOAH, K. K. ADIEPON-. See ADIEPON-YAMOAH, K. K.
Yeast infections and immunosuppressive agents, 28